Patents by Inventor Zhoufeng Chen
Zhoufeng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11252121Abstract: Embodiments of the disclosure provide methods and devices for sending messages. The method can include: storing identifiers corresponding to one or more messages that are to be sent in a first message identifier queue; storing identifiers corresponding to one or more messages that are being sent in a second message identifier queue; acquiring an identifier corresponding to a message in the first message identifier queue; moving the identifier to the second message identifier queue; and sending the message according to a sending order associated with the identifier in the second message identifier queue.Type: GrantFiled: September 21, 2018Date of Patent: February 15, 2022Assignee: ALIBABA GROUP HOLDING LIMITEDInventors: Jianfeng Chen, Pan Zeng, Hui Chen, Zhoufeng Chen
-
Patent number: 11165740Abstract: Embodiments of the present disclosure provide to a message management method and apparatus. The message management method includes: recording, in a memory, a number range of consumable messages in a message queue, wherein the number range includes numberings of the consumable messages; and adjusting the number range and managing the messages according to status changes of the messages in the message queue.Type: GrantFiled: September 21, 2018Date of Patent: November 2, 2021Assignee: Alibaba Group Holding LimitedInventors: Jianfeng Chen, Qiang Lin, Zhoufeng Chen
-
Publication number: 20190028422Abstract: Embodiments of the present disclosure provide to a message management method and apparatus. The message management method includes: recording, in a memory, a number range of consumable messages in a message queue, wherein the number range includes numberings of the consumable messages; and adjusting the number range and managing the messages according to status changes of the messages in the message queue.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Inventors: Jianfeng CHEN, Qiang LIN, Zhoufeng CHEN
-
Publication number: 20190028420Abstract: Embodiments of the disclosure provide methods and devices for sending messages. The method can include: storing identifiers corresponding to one or more messages that are to be sent in a first message identifier queue; storing identifiers corresponding to one or more messages that are being sent in a second message identifier queue; acquiring an identifier corresponding to a message in the first message identifier queue; moving the identifier to the second message identifier queue; and sending the message according to a sending order associated with the identifier in the second message identifier queue.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Inventors: Jianfeng CHEN, Pan ZENG, Hui CHEN, Zhoufeng CHEN
-
Publication number: 20140351960Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: November 22, 2013Publication date: November 27, 2014Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Publication number: 20130091591Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: August 29, 2012Publication date: April 11, 2013Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Publication number: 20110195901Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: April 1, 2011Publication date: August 11, 2011Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 7939071Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: GrantFiled: September 25, 2009Date of Patent: May 10, 2011Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 7741272Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: GrantFiled: July 15, 2005Date of Patent: June 22, 2010Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Publication number: 20100130419Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: September 25, 2009Publication date: May 27, 2010Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: HAI U. WANG, ZHOUFENG CHEN, DAVID J. ANDERSON
-
Patent number: 7700297Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: GrantFiled: February 18, 2005Date of Patent: April 20, 2010Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 7595044Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: GrantFiled: January 4, 2005Date of Patent: September 29, 2009Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Publication number: 20060288434Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: January 4, 2005Publication date: December 21, 2006Applicant: California Institute of TechnologyInventors: Hai Wang, Zhoufeng Chen, David Anderson
-
Publication number: 20060035328Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: ApplicationFiled: July 15, 2005Publication date: February 16, 2006Applicant: California Institute of TechnologyInventors: Hai Wang, Zhoufeng Chen, David Anderson
-
Publication number: 20050204412Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: ApplicationFiled: February 18, 2005Publication date: September 15, 2005Applicant: California Institute of TechnologyInventors: Hai Wang, Zhoufeng Chen, David Anderson
-
Patent number: 6916625Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: GrantFiled: June 10, 2003Date of Patent: July 12, 2005Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 6887674Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: GrantFiled: October 13, 2000Date of Patent: May 3, 2005Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 6864227Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: GrantFiled: May 28, 1998Date of Patent: March 8, 2005Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Publication number: 20030207447Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: ApplicationFiled: June 10, 2003Publication date: November 6, 2003Inventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 6579683Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.Type: GrantFiled: March 30, 2001Date of Patent: June 17, 2003Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson